Fascinating work from Stanford Medicine, combining cryo-EM and “freeze trapping” to elucidate the sequence of structural changes underlying G-protein activation. I love seeing novel technological approaches continue to improve our understanding of GPCR biology. nature.com/articles/s4158…

Exciting news as our PNH therapy received a positive CHMP opinion, bringing it one step closer to becoming the first oral monotherapy available in Europe for adults with this chronic blood disease. Congrats to all who have been involved in the development of this medicine, and

I’m excited to share that Novartis will be collaborating with Deciphex to develop potentially transformative #AI-based approaches aimed to improve efficiency and accuracy of preclinical safety studies to help bring medicines to patients faster. deciphex.com/news/deciphex-…

Pleased to share this milestone, which moves us closer to bringing a potential #malaria treatment to people of all ages, including vulnerable newborns. I couldn’t be prouder of our commitment at Novartis to fighting this devastating disease.

I’m proud of our commitment at Novartis to fighting malaria. The global community has made significant progress against this disease over the past few decades, but there is still much more that needs to be done. We must continue to work together to deliver transformative

We’re excited to have entered into an agreement to extend and expand our research collaboration with PeptiDream. Our companies have made tremendous progress in identifying peptides with potential to enable novel radioligand therapies and more, and I look forward to our continued

I’m thrilled to share that Novartis has agreed to acquire Mariana Oncology, expanding on our scientific leadership in the #RLT space. We look forward to working with the Mariana team to continue building on their innovative work and together advance potential next-gen therapeutic

Congratulations to Google Deep Mind and our partners at Isomorphic Labs for the remarkable development of Alphafold 3 (nature.com/articles/s4158…) which now has greatly enhanced ability to model proteins in complex with multiple binding partners including DNA, RNA and small molecule

The fight against malaria has been marked by numerous highs and lows, but our commitment to eliminate the disease remains unwavering. We need to act now to make malaria a problem of the past. #WHA77 #EndMalaria #Malaria Harvard T.H. Chan School of Public Health RBM Partnership

I’m pleased to share this positive Phase III data for our investigational treatment for Ph+ CML-CP in newly diagnosed adult patients. Congrats to all involved from Novartis R&D and thank you to the patients and clinicians who participated in the trial! novartis.com/news/media-rel…

It was a pleasure to join leaders of our LGBTQI community and so many more Cambridge colleagues for this year’s Pride flag-raising event. Thank you to all who attended to celebrate equity, inclusion, dignity, and visibility to kick off #PrideMonth this year.

Excited to see this published in Science Magazine—our team’s paper on the discovery of molecular glue degraders to induce fetal hemoglobin—a potential avenue toward creating an accessible oral therapy for #sicklecelldisease. Congrats to Pamela Ting, Jay Bradner, M.D. and all involved

This is an exciting opportunity to learn from brilliant mentors while applying your AI and #datascience skills in the field of drug discovery. Recent PhD graduates are encouraged to apply by July 29. linkedin.com/posts/novartis…

I had a wonderful visit to our San Diego Biomedical Research hub where I met with many of our remarkable scientists, including contributors to this ingenious technology. Exciting to see the work spark valuable insights in the hunt for new heart disease drugs.

I’m pleased to share that Novartis has entered into a collaboration agreement with Dren Bio to discover and advance novel antibody-based immune cell engagers for certain cancers. businesswire.com/news/home/2024…

This exciting news from the FDA brings a new treatment option to the US for reduction of proteinuria in certain adults with IgA nephropathy. Congratulations to all who helped achieve this milestone, including the many patients and clinicians who participated in clinical trials.

So glad I could be present to celebrate this milestone. FMI science is a research powerhouse. I have no doubt this amazing new facility will be the home of many transformativediscoveries in the coming years.